Note: You are reading this message either because your browser is not standards-compliant, or your browser failed to load our css files.

A description of the content follows : In a recent research report published by the Cohen Independent Research Group, the current $3.50 per share price of biotech Novelos Therapeutics, Inc. (NVLT) could more than double over the next 12 months. The 12-month forecasts in the report are painted within three scenarios and result in a hierarchy of share price targets ranging from $7.20 to $9.50 to $14.20.